Rescue therapy in acute severe ulcerative colitis: ACG 2025
“In patients with ASUC failing to adequately respond to intravenous corticosteroids (IVCS) by 3 days, we recommend medical rescue therapy with infliximab or cyclosporine (Strong recommendation, moderate quality of evidence).” (opens the source at this quote in a new tab)
“In patients with ASUC who achieve remission with cyclosporine treatment, we suggest maintenance of remission with thiopurines (Conditional recommendation, low quality of evidence).” (opens the source at this quote in a new tab)
“In patients with ASUC, the choice between infliximab and cyclosporine should be based on provider experience with the agent, history of prior failure of immunomodulator or anti-TNF therapy, and serum albumin.” (opens the source at this quote in a new tab)
“By contrast, because cyclosporine is used less frequently and only at select centers, its use in steroid-refractory colitis should be restricted to providers who are familiar with dosing, monitoring trough concentrations, and managing adverse effects.” (opens the source at this quote in a new tab)
Tacrolimus in steroid-refractory disease: ACG 2025
Cyclosporine compared with infliximab: ECCO 2026
Third-line sequential rescue therapy: ECCO 2026
Calcineurin inhibitors prohibited during obefazimod open-label maintenance